Insiders · NBIX

Gary A Lyons

Director at Neurocrine Biosciences Inc (NBIX)

Gary A Lyons has filed 44 insider reports with the SEC since January 2021, as director at Neurocrine Biosciences Inc (NBIX), director at Travere Therapeutics, Inc. (TVTX) and director at Rigel Pharmaceuticals Inc (RIGL) and at 2 more companies. In the last 12 months Gary A Lyons sold $5.72M of stock on the open market. In the latest filing, on November 19, 2026, Gary A Lyons sold 15,000 shares of Neurocrine Biosciences Inc (NBIX) for $2.47M at an average of $164.87.

Filings
44
Companies
5
Bought on market
None
Sold on market
$18.3M

Companies where Gary A Lyons is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Neurocrine Biosciences Inc logo
NBIX
Neurocrine Biosciences Inc
Director122,141$16.8M$156.59Nov 19, 2026
Travere Therapeutics, Inc. logo
TVTX
Travere Therapeutics, Inc.
Director61,500$1.55M$48.30Aug 19, 2026
Rigel Pharmaceuticals Inc logo
RIGL
Rigel Pharmaceuticals Inc
Director75,000$41.19Jul 12, 2023
Eledon Pharmaceuticals, Inc. logo
ELDN
Eledon Pharmaceuticals, Inc.
Director$1.90May 2, 2023
Brickell Biotech, Inc. logo
BBI
Brickell Biotech, Inc.
DirectorMay 17, 2022

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Gary A Lyons with

Other insiders at the same companies

Questions about Gary A Lyons

What is Gary A Lyons's role at Neurocrine Biosciences Inc?
Gary A Lyons reports to the SEC as director at Neurocrine Biosciences Inc (NBIX), according to the latest filing on November 19, 2026. Gary A Lyons has also filed as director at Travere Therapeutics, Inc. (TVTX), director at Rigel Pharmaceuticals Inc (RIGL), director at Eledon Pharmaceuticals, Inc. (ELDN) and director at Brickell Biotech, Inc. (BBI).
How many shares does Gary A Lyons own?
After the latest filing that states it, Gary A Lyons directly owned 122,141 shares of Neurocrine Biosciences Inc (NBIX), 61,500 shares of Travere Therapeutics, Inc. (TVTX) and 75,000 shares of Rigel Pharmaceuticals Inc (RIGL). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Gary A Lyons bought or sold stock recently?
The most recent open-market sale was on November 17, 2026: sold 15,000 shares of Neurocrine Biosciences Inc (NBIX) for $2.47M at an average of $164.87.
How do I get alerts when Gary A Lyons files?
Follow Gary A Lyons on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale. Gary A Lyons filed 1 time in the last 90 days.

From SEC Forms 3, 4, 5 and 144 filed by Gary A Lyons (SEC CIK 0001123343). Totals count each trade once, skipping amendments whose original is on file, from Jan 28, 2021 on. View on SEC EDGAR · Get this as JSON